Newborn screening for spinal muscular atrophy (SMA) is a groundbreaking policy that will save lives and improve outcomes for countless families. Beginning in 2027, all newborns in England will be tested for SMA, allowing for early treatment and support. This milestone, however, raises a critical question: why are other serious genetic conditions like Duchenne muscular dystrophy (DMD) still left out of newborn screening programmes?
Why SMA Screening Matters
Early diagnosis of SMA means children can access life-changing therapies such as nusinersen and risdiplam before symptoms appear. This dramatically improves motor function and survival. The campaign to include SMA in the newborn screening panel was a hard-fought victory, driven by families and advocacy groups.
Get the #1 Wireless Door Camera
REOLINK Bestseller: 2K Weatherproof Video Doorbell, No Monthly Fees.
The Case for Duchenne Muscular Dystrophy
About 100 boys are born with DMD each year in the UK. The condition causes progressive muscle weakness and is often diagnosed only after years of uncertainty. Although new treatments like Givinostat offer hope, early diagnosis remains vital. It allows families to access specialist care, plan for the future, and benefit from emerging therapies. Research shows that delayed diagnosis leads to multiple GP visits, misdiagnoses, and unnecessary stress for families.
Comparison: SMA vs. DMD Newborn Screening
| Condition | Annual Births (UK) | Current Screening | Treatment Available |
|---|---|---|---|
| Spinal Muscular Atrophy (SMA) | ~50 | Yes (from 2027) | Nusinersen, Risdiplam, Zolgensma |
| Duchenne Muscular Dystrophy (DMD) | ~100 | No | Givinostat, Corticosteroids, Gene therapy (emerging) |
Key Takeaways
- Newborn screening for SMA is a proven success that saves lives and reduces diagnostic delays.
- Duchenne muscular dystrophy affects three times more infants than SMA each year, yet lacks newborn screening.
- Early diagnosis of DMD enables access to specialist care, clinical trials, and family planning.
- Policy must expand to include DMD and other rare genetic conditions to ensure every child gets the best start.
Frequently Asked Questions
What is newborn screening?
Newborn screening is a public health programme that tests infants for certain genetic, metabolic, and developmental disorders shortly after birth. Early detection allows for prompt treatment and management.
How is SMA screened in newborns?
SMA is detected via a blood spot test that looks for a missing or mutated SMN1 gene. The same heel-prick test used for other conditions can include SMA.
Could Duchenne muscular dystrophy be added to newborn screening?
Yes. Several pilot studies have shown that screening for DMD using a simple blood test is both feasible and cost-effective. Advocates are pushing for its inclusion in the national panel.
The momentum from the SMA victory should inspire policymakers to broaden newborn screening programmes. Every child deserves a timely diagnosis, and every family deserves the chance to plan and thrive. It is time to include Duchenne muscular dystrophy and other rare conditions in routine testing.
Home Decor Shop
Acacia frida deluxe solid wood bed frame |
Bedroom bench |
Bed chest drawers |
Lingerie dresser |
Frame base |
Mirror with jewelry storage |
30 Bathroom Vanity |
Memory foam queen mattress |
Mattresses for back pain |
Nightstand set of 2 |
Grand Goldman Shop |
Civil Lawyer
Deutschland Trikot WM 2026
